Efficacy and Safety of Loxapine in Acute Agitation
The Primary Care Companion For CNS Disorders · 2023
DOI: 10.4088/pcc.23r03552 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift The Primary Care Companion For CNS Disorders, 2023. Verfasst von Camille Lebel und 3 weiteren Autor:innen. Beteiligte Einrichtung: Psychiatry Internship Program, University of Burgundy, Dijon, France. Hauptthemen laut MEDLINE: Loxapine, Antipsychotic Agents.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Psychiatry Internship Program, University of Burgundy, Dijon, France.
- Corresponding Author: Camille Lebel, MD, Psychiatry Internship Program, University of Burgundy, 21000 Dijon, France (camillelebel@outlook.fr).
- Service de Psychiatrie Adultes, Centre Hospitalier Universitaire, Dijon, France.
- INSERM, LNC-UMR 1231, University of Burgundy, Dijon, France.
Zitieren
APA
Lebel, C., Endomba, F. T., Chabridon, G., & Chauvet-Gélinier, J. C. (2023). Efficacy and Safety of Loxapine in Acute Agitation. The Primary Care Companion For CNS Disorders. https://doi.org/10.4088/pcc.23r03552
Vancouver
Lebel C, Endomba FT, Chabridon G, Chauvet-Gélinier JC. Efficacy and Safety of Loxapine in Acute Agitation. The Primary Care Companion For CNS Disorders. 2023. doi:10.4088/pcc.23r03552
BibTeX
@article{Lebel2023,
author = {Lebel, Camille and Endomba, Francky Teddy and Chabridon, Guillaume and Chauvet-Gélinier, Jean-Christophe},
title = {Efficacy and Safety of Loxapine in Acute Agitation},
journal = {The Primary Care Companion For CNS Disorders},
year = {2023},
doi = {10.4088/pcc.23r03552}
}
EUVIMED